Simulations Plus Announced Transfer or Voluntary Withdrawal of Listing

Simulations Plus, Inc. (SLP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 1 Exhibit 99.1 Simulations Plus Announces Completion of Acquisition by Altaris RESEARCH TRIANGLE PARK, NC, October 6, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that adva

Simulations Plus, Inc. (SLP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 slp-2026531xexx991x263.htm EX-99.1 Document Exhibit 99.1 Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results RESEARCH TRIANGLE PARK, NC, July 9, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-

RBC Capital Markets initiated coverage of Sylvania Platinum (AIM:SLP) with an Outperform rating and a 175p target, implying 90% upside from 92p. RBC says the shares trade at 0.6x net asset value and 20% free cash flow yield on 2027 estimates, reflecting “mispricing.” It cites a potential production cliff after 2030 as waste feed runs down, but expects the Thaba joint venture to add 26% to production and forecasts average dividend yields of 14.4% over three years.

Vaxcyte announced a $500M equity offering and $500M in convertible notes. The notes have a 1.50% interest rate, mature in 2032, and include a 40% conversion premium at $89.60 per share. They can be converted, repurchased, or redeemed under certain conditions.

Skydance SKYD announced that nearly all bondholders participated in its debt tender and exchange offers after acquiring Warner Bros. Discovery WBD. About 98.83% of notes in the cash tender offers and 99.15% in the exchange offers were tendered. Eligible holders received new Skydance notes for their existing WBD notes, which will be retired and canceled.

Vaxcyte, Inc. (NASDAQ: PCVX) raised about US$1B through concurrent stock, warrant, and convertible-note offerings. The company plans to use proceeds for clinical trials, manufacturing, and potential U.S. launch of its pneumococcal vaccine VAX-31. Vaxcyte's shares were trading at US$56.48 on Oct. 2, before the offering.